Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 15/20 | 0.64 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.51 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9824148 | 0.87 | AKR1B1 (0.59) | AKR1B1AKR1B10MAPTAKR1A1CTNNB1 | |
| SCHEMBL7177095 | 0.83 | AKR1B1 (0.55) | AKR1B1AKR1B10MAPTAKR1A1 | |
| SCHEMBL6605552 | 0.82 | MAP3K14 (0.49) | AKR1B1 | |
| SCHEMBL6578141 | 0.82 | AKR1B1 (0.44) | AKR1B1MAPTCTNNB1 | |
| SCHEMBL5399703 | 0.82 | MAP3K14 (0.49) | AKR1B1 | |
| SCHEMBL6605548 | 0.82 | MAP3K14 (0.49) | AKR1B1 | |
| SCHEMBL10651444 | 0.81 | AKR1B1 (0.59) | AKR1B1AKR1B10MAPTAKR1A1CTNNB1 | |
| SCHEMBL10569394 | 0.81 | AKR1B1 (0.59) | AKR1B1AKR1B10MAPTAKR1A1CTNNB1 | |
| SCHEMBL10919189 | 0.81 | AKR1B1 (0.59) | AKR1B1AKR1B10MAPTAKR1A1CTNNB1 | |
| SCHEMBL1690422 | 0.81 | AKR1B1 (0.59) | AKR1B1AKR1B10MAPTAKR1A1CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1012140-B1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRAZENECA AB (SE) | 2004-09-29 | — | — | EP | disclosed |
| US-6576657-B2 | Nitrogen containing heterocyclic compounds useful as anticoagulants | ASTRAZENECA AB (SE) | 2003-06-10 | — | — | US | disclosed |
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB | 2002-02-21 | — | — | US | disclosed |
| US-6265397-B1 | Amidino derivatives and their use as thrombin inhibitors | ASTRAZENECA AB (SE) | 2001-07-24 | — | — | US | disclosed |
| EP-1012140-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | AstraZeneca AB (SE) | 2000-06-28 | — | — | EP | disclosed |
| WO-1998057932-A1 | NEW AMIDINO DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS | ASTRA AKTIEBOLAG (SE) | 1998-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020022612-A1 | New amidino derivatives and their use as thrombin inhibitors | SERPINC1, SERPINE1, SERPINB1 | AKR1B1 1664/4885AKR1B10 2785/4885MAPT 4837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.